This year, the first batch of domestic varieties will usher in generic competition!

As of December 7 this year, a total of 45 varieties have been approved for the first time in China In recent years, CFDA has become more and more strict with the drug review and approval system, and the process of a new drug from research and development to marketing is becoming more and more difficult Any negligence or omission in any link may cause a candidate drug to die Once the drug is successfully launched, the return is amazing, especially for those products that rush to land According to the statistics of CPM database of China Pharmaceutical Industry Information Center, as of December 7 this year, a total of 45 varieties have been approved for listing for the first time in China, including 3 domestic enterprises and 42 import enterprises Data source of varieties approved for listing for the first time in 2017 (as of December 7): CPM database of China Pharmaceutical Industry Information Center from the perspective of treatment field, the varieties approved for listing for the first time in China this year show the trend of anti infective drugs and anti-tumor drugs playing the leading role Looking at these two kinds of drug markets, under the influence of China's drug regulatory policy and drug safety system, they have shown industrial scale There are many kinds of anti infective drugs, and the competition is fierce However, there are not many kinds of anti viral drugs, such as anti hepatitis virus and anti AIDS drugs on the market The market is relatively blank, which is an opportunity With a high growth rate of 2-digit, the field of tumor diseases attracts pharmaceutical enterprises to join the R & D army and seize the leading position in the domestic market, so as to seize the opportunity to expand the territory of Xinjiang In 2017, the data source of analysis in the field of variety treatment approved for listing for the first time in China: CPM database of China Pharmaceutical Industry Information Center, however, it is easy to fight against the country and difficult to keep the country At present, zoelacetan injection, suofebuwei tablet, azacytidine injection, etc have all faced the attack of generic drugs The first enterprises applying for the generic drugs are Chongqing shenghuaxi Pharmaceutical Co., Ltd., Beijing Kaiyin Technology Co., Ltd and Zhengda Tianqing Pharmaceutical Co., Ltd In terms of the number of domestic enterprises, there are more than 10 varieties declared, accounting for 28.9%, while 33.3% have not yet been declared by domestic enterprises Competition of the first approved varieties in China in 2017 statistics of the first approved varieties in China in 2017 according to the number of domestic enterprises declared in 2017 the first approved varieties in China have not yet been declared by domestic enterprises data source: CPM database of China Pharmaceutical Industry Information Center